Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease
Globe Newswire - Dec 18th, 2024
Tessera Therapeutics, a biotechnology company specializing in genome engineering, has announced a partnership with the Bill & Melinda Gates Foundation to co-fund its in vivo sickle cell disease (SCD) program. The Gates Foundation will provide an initial investment that could total up to $50 million to bring Tessera's SCD treatment to clinical development. Tessera is working on a one-time intravenous treatment using its Gene WritingTM technology to correct the sickle mutation without the need for stem cell mobilization or chemotherapy. This treatment is facilitated by Tessera's proprietary non-viral lipid nanoparticle delivery platform, targeting the delivery to long-term hematopoietic stem cells. The aim is to offer a safer, more scalable treatment compared to current options. Tessera believes this will revolutionize the treatment landscape for SCD globally. The company was founded in 2018 by Flagship Pioneering and focuses on developing transformative genetic medicines.
RATING
The article provides an informative announcement regarding Tessera Therapeutics' collaboration with the Bill & Melinda Gates Foundation on a new approach to treating sickle cell disease. While the article is clear and concise, it primarily reflects the perspective of Tessera Therapeutics, with limited external viewpoints and source diversity.
RATING DETAILS
The article appears factually accurate, providing specific details about the funding and objectives of the collaboration. However, it lacks independent verification or third-party perspectives to confirm these details.
The article predominantly presents Tessera Therapeutics' perspective, with minimal coverage of other viewpoints or potential challenges. Additional perspectives, such as those from scientific experts or patient advocacy groups, would enhance balance.
The language is clear and free of jargon, making the article accessible to a broad audience. The structure is logical, with a straightforward presentation of the facts.
The article cites Tessera Therapeutics and mentions its collaboration with a reputable organization, the Bill & Melinda Gates Foundation. However, it does not include external sources or expert commentary to corroborate the claims.
The article provides a clear account of the funding and goals but lacks disclosure of any potential conflicts of interest or affiliations that might influence the reporting. The promotional tone suggests a need for more transparency regarding the company's motivations.